JP2021073256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021073256A5 JP2021073256A5 JP2021012044A JP2021012044A JP2021073256A5 JP 2021073256 A5 JP2021073256 A5 JP 2021073256A5 JP 2021012044 A JP2021012044 A JP 2021012044A JP 2021012044 A JP2021012044 A JP 2021012044A JP 2021073256 A5 JP2021073256 A5 JP 2021073256A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- disease
- preparation containing
- compound
- purity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 29
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 7
- 208000027866 inflammatory disease Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- JHGGOTFKWARTGB-UHFFFAOYSA-N CS(=O)(=O)O.C(C1=CN=CC=C1)(=O)O Chemical compound CS(=O)(=O)O.C(C1=CN=CC=C1)(=O)O JHGGOTFKWARTGB-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 201000004810 Vascular dementia Diseases 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- FSSOYPTUNGNSQS-UHFFFAOYSA-N pyridine-3-carboxylic acid;sulfuric acid Chemical compound [H+].[O-]S([O-])(=O)=O.OC(=O)C1=CC=C[NH+]=C1 FSSOYPTUNGNSQS-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 150000004686 pentahydrates Chemical class 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000018093 autoimmune cholangitis Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1507031.1A GB201507031D0 (en) | 2015-04-24 | 2015-04-24 | New pharmaceutical salt forms |
| GB1507031.1 | 2015-04-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555499A Division JP2018513189A (ja) | 2015-04-24 | 2016-04-22 | セミカルバジド感受性アミンオキシダーゼ（ｓｓａｏ）の阻害剤の医薬的塩形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021073256A JP2021073256A (ja) | 2021-05-13 |
| JP2021073256A5 true JP2021073256A5 (enExample) | 2021-08-12 |
Family
ID=53488629
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555499A Pending JP2018513189A (ja) | 2015-04-24 | 2016-04-22 | セミカルバジド感受性アミンオキシダーゼ（ｓｓａｏ）の阻害剤の医薬的塩形態 |
| JP2021012044A Pending JP2021073256A (ja) | 2015-04-24 | 2021-01-28 | セミカルバジド感受性アミンオキシダーゼ（ｓｓａｏ）の阻害剤の医薬的塩形態 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555499A Pending JP2018513189A (ja) | 2015-04-24 | 2016-04-22 | セミカルバジド感受性アミンオキシダーゼ（ｓｓａｏ）の阻害剤の医薬的塩形態 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10316034B2 (enExample) |
| EP (1) | EP3286190B1 (enExample) |
| JP (2) | JP2018513189A (enExample) |
| KR (1) | KR20170139045A (enExample) |
| CN (2) | CN107531702A (enExample) |
| AR (1) | AR104360A1 (enExample) |
| AU (1) | AU2016251707B2 (enExample) |
| BR (1) | BR112017020016A2 (enExample) |
| CA (1) | CA2979144A1 (enExample) |
| DK (1) | DK3286190T3 (enExample) |
| EA (1) | EA035668B1 (enExample) |
| ES (1) | ES2804155T3 (enExample) |
| GB (1) | GB201507031D0 (enExample) |
| HU (1) | HUE049985T2 (enExample) |
| IL (1) | IL254153A0 (enExample) |
| MX (1) | MX2017013049A (enExample) |
| PT (1) | PT3286190T (enExample) |
| SG (1) | SG11201707867WA (enExample) |
| WO (1) | WO2016170351A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201507036D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Crystalline enzyme inhibitor compound |
| GB201507048D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Treatment of pain |
| GB201618029D0 (en) | 2016-10-25 | 2016-12-07 | Proximagen Ltd | New process |
| CN108017634A (zh) * | 2017-12-15 | 2018-05-11 | 清华大学 | 一种制备吡咯并多环衍生物的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4141899A (en) | 1976-01-07 | 1979-02-27 | Societa' Farmaceutici Italia S.P.A. | 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives |
| IT1098015B (it) | 1978-08-07 | 1985-08-31 | Farmaceutici Italia | Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati |
| EP1173438A1 (en) * | 1999-04-16 | 2002-01-23 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| US6908926B1 (en) | 1999-04-16 | 2005-06-21 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| SE0004101D0 (sv) | 2000-11-09 | 2000-11-09 | Pharmacia Ab | New use |
| AU2002214505A1 (en) | 2000-11-09 | 2002-05-21 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives |
| CA2556914A1 (en) * | 2004-02-25 | 2005-09-09 | La Jolla Pharmaceutical Company | Amines and amides for the treatment of diseases |
| US20070066646A1 (en) | 2005-08-02 | 2007-03-22 | Genmedica Therapeutics Sl | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof |
| EP2029164B1 (en) | 2006-06-07 | 2015-12-23 | The Board of Trustees of the Leland Stanford Junior University | Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy |
| JP5613671B2 (ja) * | 2008-09-16 | 2014-10-29 | プロキシマジェン エルティーディーＰｒｏｘｉｍａｇｅｎ Ｌｔｄ． | 新規化合物ｉｉ |
| BRPI0918602B8 (pt) * | 2008-09-16 | 2021-05-25 | Benevolentai Cambridge Ltd | inibidores da atividade de ssao, seu uso, e formulação farmacêutica |
| GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| GB201115853D0 (en) * | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
| IN2014DN01883A (enExample) * | 2011-09-14 | 2015-05-15 | Proximagen Ltd | |
| GB201304526D0 (en) * | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| US20160113893A1 (en) | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| HUE042625T2 (hu) | 2014-04-15 | 2019-07-29 | Pecsi Tudomanyegyetem | Szemikarbazid-szenzitiv amin-oxidáz gátlók fájdalomcsillapítóként való alkalmazásra traumás neuropátiában és neurogén gyulladásban |
| GB201507036D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Crystalline enzyme inhibitor compound |
| GB201507048D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Treatment of pain |
-
2015
- 2015-04-24 GB GBGB1507031.1A patent/GB201507031D0/en not_active Ceased
-
2016
- 2016-04-22 JP JP2017555499A patent/JP2018513189A/ja active Pending
- 2016-04-22 EA EA201792121A patent/EA035668B1/ru not_active IP Right Cessation
- 2016-04-22 ES ES16719892T patent/ES2804155T3/es active Active
- 2016-04-22 KR KR1020177032022A patent/KR20170139045A/ko not_active Withdrawn
- 2016-04-22 CA CA2979144A patent/CA2979144A1/en not_active Abandoned
- 2016-04-22 EP EP16719892.8A patent/EP3286190B1/en active Active
- 2016-04-22 CN CN201680023326.3A patent/CN107531702A/zh active Pending
- 2016-04-22 SG SG11201707867WA patent/SG11201707867WA/en unknown
- 2016-04-22 AU AU2016251707A patent/AU2016251707B2/en not_active Ceased
- 2016-04-22 DK DK16719892.8T patent/DK3286190T3/da active
- 2016-04-22 WO PCT/GB2016/051119 patent/WO2016170351A1/en not_active Ceased
- 2016-04-22 BR BR112017020016A patent/BR112017020016A2/pt not_active IP Right Cessation
- 2016-04-22 US US15/567,536 patent/US10316034B2/en active Active
- 2016-04-22 PT PT167198928T patent/PT3286190T/pt unknown
- 2016-04-22 AR ARP160101126A patent/AR104360A1/es unknown
- 2016-04-22 MX MX2017013049A patent/MX2017013049A/es unknown
- 2016-04-22 HU HUE16719892A patent/HUE049985T2/hu unknown
- 2016-04-22 CN CN202110072000.2A patent/CN112851669A/zh active Pending
-
2017
- 2017-08-24 IL IL254153A patent/IL254153A0/en unknown
-
2021
- 2021-01-28 JP JP2021012044A patent/JP2021073256A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021073256A5 (enExample) | ||
| BR112021007428A2 (pt) | processos inéditos | |
| JP2022017447A5 (enExample) | ||
| JP2020128376A5 (enExample) | ||
| JP2021073259A5 (enExample) | ||
| JP2017510624A5 (enExample) | ||
| US10821108B2 (en) | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide | |
| JPH06504275A (ja) | （−）−［［４−（１，４，５，６−テトラヒドロ−４−メチル−６−オキソ−３−ピリダジニル）フェニル］ヒドラゾノ］プロパンジニトリル | |
| JP2013529647A5 (enExample) | ||
| JP2012506368A5 (enExample) | ||
| JP2015214574A (ja) | チオトロピウム臭化物の無水物 | |
| TW201302761A (zh) | Ｈｉｖ抑制劑之固態形式 | |
| JP2016534133A (ja) | （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用 | |
| JP2006519824A5 (enExample) | ||
| JP2022160667A (ja) | アクリジニウム臭化物の製造方法 | |
| EP3279195A1 (en) | Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine | |
| CN114127061A (zh) | (r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺酰基)-1-氟乙基)-n-(异噁唑-3-基)哌啶-1-甲酰胺的多晶型物形式 | |
| JPWO2022078352A5 (enExample) | ||
| JP6845565B2 (ja) | インドール酢酸アミド誘導体 | |
| JP2021514944A (ja) | オキソピコリナミド誘導体の結晶形及びそれらの製造方法 | |
| AU2022351081A1 (en) | Cyclohexyl beta-hydroxy alkyl amines and medical uses thereof | |
| CN104768927B (zh) | (3s,3s’)‑4,4’‑二硫烷二基双(3‑氨基丁烷‑1‑磺酸)合l‑赖氨酸的新的结晶相 | |
| JPWO2019024845A5 (enExample) | ||
| JPS60116678A (ja) | ｎ‐プロパノールアミン誘導体エーテル | |
| US20220402861A1 (en) | A Crystalline form of (R)-terbutaline Hydrochloride |